Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 7/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.45 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
| ▸ | CTSK | P43235 | 1/20 | 0.45 |
| ▸ | DHPS | P49366 | 1/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4064654 | 0.92 | L3MBTL1 (0.52) | PIK3CAL3MBTL1HSD17B10CYP1A2CYP3A4 | |
| SCHEMBL4065446 | 0.84 | PIK3CA (0.51) | PIK3CAL3MBTL1HSD17B10CYP1A2CYP3A4 | |
| SCHEMBL6586305 | 0.82 | DHPS (0.55) | PIK3CAL3MBTL1HSD17B10TSHRMAPT | |
| SCHEMBL4062185 | 0.81 | DHPS (0.51) | PIK3CAL3MBTL1HSD17B10CYP1A2CYP3A4 | |
| SCHEMBL4059458 | 0.80 | L3MBTL1 (0.52) | PIK3CAL3MBTL1HSD17B10CYP1A2CYP3A4 | |
| SCHEMBL7850538 | 0.75 | MAPT (0.48) | PIK3CAL3MBTL1HSD17B10CYP1A2MAPK1 | |
| SCHEMBL5753620 | 0.74 | PIK3CA (0.61) | PIK3CAL3MBTL1HSD17B10CYP1A2CYP3A4 | |
| SCHEMBL11864650 | 0.73 | MAPT (0.52) | PIK3CAL3MBTL1HSD17B10MAPK1MAPT | |
| SCHEMBL7853910 | 0.73 | EDNRA (0.50) | PIK3CAL3MBTL1MAPK1MAPTPIK3CD | |
| SCHEMBL7849633 | 0.73 | MAPT (0.47) | PIK3CAL3MBTL1MAPK1MAPTPIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1322624-B1 | ARYLALKANE-SULFONAMIDES HAVING ENDOTHELIN-ANTAGONIST ACTIVITY | ACTELION PHARMACEUTICALS LTD (CH) | 2009-10-21 | — | — | EP | disclosed |
| US-7091201-B2 | Arylalkane-sulfonamides having endothelin-antagonist activity | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-08-15 | — | — | US | disclosed |
| US-20040102464-A1 | Arylalkane-sulfonamides having endothelin-antagonist activity | ACTELION PHARMACEUTICALS LTD. (CH) | 2004-05-27 | — | — | US | disclosed |
| EP-1322624-A1 | ARYLALKANE-SULFONAMIDES HAVING ENDOTHELIN-ANTAGONIST ACTIVITY | Actelion Pharmaceuticals Ltd. (CH) | 2003-07-02 | — | — | EP | disclosed |
| WO-2002024665-A1 | ARYLALKANE-SULFONAMIDES HAVING ENDOTHELIN-ANTAGONIST ACTIVITY | ACTELION PHARMACEUTICALS LTD (CH) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102464-A1 | Arylalkane-sulfonamides having endothelin-antagonist activity | EDNRA, EDNRB, ECE2 | PIK3CA 1980/4885L3MBTL1 4881/4885HSD17B10 3249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.